Tool Kit

Teva Announces Exclusive Launch of Generic Actonel® Tablets in the United States

JERUSALEM--(BUSINESS WIRE)--Jun. 1, 2015--
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the launch of
the generic equivalent to Actonel® (risedronate sodium)
Tablets, 5 mg, 30 mg, and 35 mg, in the United States. Teva was first to
file, making the product eligible for 180 days of market exclusivity.
Risedronate sodium tablets are used to treat or prevent osteoporosis in
women after menopause. Risedronate sodium tablets help increase bone
mass and help reduce the chance of having a spinal or non-spinal
fracture (break). Risedronate sodium tablets are also used to treat or
prevent osteoporosis in either men or women who are taking
corticosteroid medicines, and to treat Paget’s disease of the bone.

Risedronate sodium tablets, USP are the second approved product to treat
osteoporosis in Teva’s generic portfolio. Approximately 54 million
Americans have low bone mass and osteoporosis, a condition that causes
the bones to become weak and brittle. Anyone can develop osteoporosis
but studies suggest it is most common in older women and patients taking
specific medications. As a leading global pharmaceutical company, Teva
is committed to care in women’s health and bringing to market
high-quality, accessible generic medicines for doctors, pharmacists, and
most importantly, patients.

Actonel® (risedronate sodium) Tablets marketed by Actavis had
annual sales of approximately $157 million in the United States,
according to IMS data as of December 2014.

About Risedronate Sodium Tablets, USP

Risedronate Sodium Tablets, USP are indicated for: treatment and
prevention of postmenopausal osteoporosis; treatment to increase bone
mass in men with osteoporosis; treatment and prevention of
glucocorticoid-induced osteoporosis; and treatment of Paget’s disease.

Limitations of use: Optimal duration of use has not been determined. For
patients at low-risk for fracture, consider drug discontinuation after 3
to 5 years of use.

Important Safety Information

Risedronate sodium tablets, USP are contraindicated in patients with:abnormalities
of the esophagus which delay esophageal emptying such as stricture or
achalasia; inability to stand or sit upright for at least 30
minutes; hypocalcemia; or known hypersensitivity to any component of
this product. Angioedema, generalized rash, bullous skin reactions,
Stevens-Johnson syndrome and toxic epidermal necrolysis have been
reported.

Patients being treated with risedronate sodium delayed-release tablets
(Atelvia®) should not receive risedronate sodium tablets,
since both drugs contain the same active ingredient.

Risedronate may cause local irritation of the upper gastrointestinal
mucosa. Patients with known esophageal diseases, gastritis, duodenitis
or ulcers should be carefully evaluated for possible irritant effects
and a potential for worsening of the underlying disease. Esophageal
adverse experiences, some severe and requiring hospitalization, have
been reported. Patients should be instructed to discontinue risedronate
and seek medical attention if they develop dysphagia, odynophagia,
retrosternal pain or new or worsening heartburn.

Other serious adverse reactions associated with the use of risedronate
or other bisphosphonates include: hypocalcemia; osteonecrosis of the
jaw; severe and occasionally incapacitating bone, joint, and/or muscle
pain; and atypical, low-energy, or low trauma fractures of the femoral
shaft and femur.

The most common adverse reactions reported in greater than 10% of
patients treated with risedronate and with a higher frequency than
placebo are: back pain, arthralgia, abdominal pain, and dyspepsia.
Hypersensitivity reactions (angioedema, generalized rash, bullous skin
reactions, Stevens-Johnson syndrome, and toxic epidermal necrolysis),
and eye inflammation (iritis, uveitis) have been reported rarely.

About TevaTeva Pharmaceutical Industries Ltd. (NYSE and
TASE: TEVA) is a leading global pharmaceutical company that delivers
high-quality, patient-centric healthcare solutions to millions of
patients every day. Headquartered in Israel, Teva is the world’s largest
generic medicines producer, leveraging its portfolio of more than 1,000
molecules to produce a wide range of generic products in nearly every
therapeutic area. In specialty medicines, Teva has a world-leading
position in innovative treatments for disorders of the central nervous
system, including pain, as well as a strong portfolio of respiratory
products. Teva integrates its generics and specialty capabilities in its
global research and development division to create new ways of
addressing unmet patient needs by combining drug development
capabilities with devices, services and technologies. Teva's net
revenues in 2014 amounted to $20.3 billion. For more information, visit www.tevapharm.com.

Safe Harbor Statement under the U.S. Private Securities Litigation
Reform Act of 1995:This release contains forward-looking
statements, which are based on management’s current beliefs and
expectations and involve a number of known and unknown risks and
uncertainties that could cause our future results, performance or
achievements to differ significantly from the results, performance or
achievements expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such differences
include risks relating to: our ability to develop and commercialize
additional pharmaceutical products; competition for our innovative
products, especially Copaxone® (including competition from
orally-administered alternatives, as well as from potential purported
generic equivalents) and our ability to migrate users to our 40 mg/mL
version; the possibility of material fines, penalties and other
sanctions and other adverse consequences arising out of our ongoing FCPA
investigations and related matters; our ability to achieve expected
results from the research and development efforts invested in our
pipeline of specialty and other products; our ability to reduce
operating expenses to the extent and during the timeframe intended by
our cost reduction program; our ability to identify and successfully bid
for suitable acquisition targets or licensing opportunities, or to
consummate and integrate acquisitions; the extent to which any
manufacturing or quality control problems damage our reputation for
quality production and require costly remediation; increased government
scrutiny in both the U.S. and Europe of our patent settlement
agreements; our exposure to currency fluctuations and restrictions as
well as credit risks; the effectiveness of our patents, confidentiality
agreements and other measures to protect the intellectual property
rights of our specialty medicines; the effects of reforms in healthcare
regulation and pharmaceutical pricing, reimbursement and coverage;
governmental investigations into sales and marketing practices,
particularly for our specialty pharmaceutical products; adverse effects
of political or economic instability, major hostilities or acts of
terrorism on our significant worldwide operations; interruptions in our
supply chain or problems with internal or third-party information
technology systems that adversely affect our complex manufacturing
processes; significant disruptions of our information technology systems
or breaches of our data security; competition for our generic products,
both from other pharmaceutical companies and as a result of increased
governmental pricing pressures; competition for our specialty
pharmaceutical businesses from companies with greater resources and
capabilities; the impact of continuing consolidation of our distributors
and customers; decreased opportunities to obtain U.S. market exclusivity
for significant new generic products; potential liability in the U.S.,
Europe and other markets for sales of generic products prior to a final
resolution of outstanding patent litigation; our potential exposure to
product liability claims that are not covered by insurance; any failure
to recruit or retain key personnel, or to attract additional executive
and managerial talent; any failures to comply with complex Medicare and
Medicaid reporting and payment obligations; significant impairment
charges relating to intangible assets, goodwill and property, plant and
equipment; the effects of increased leverage and our resulting reliance
on access to the capital markets; potentially significant increases in
tax liabilities; the effect on our overall effective tax rate of the
termination or expiration of governmental programs or tax benefits, or
of a change in our business; variations in patent laws that may
adversely affect our ability to manufacture our products in the most
efficient manner; environmental risks; and other factors that are
discussed in our Annual Report on Form 20-F for the year ended December
31, 2014 and in our other filings with the U.S. Securities and Exchange
Commission. Forward-looking statements speak only as of the date on
which they are made and we assume no obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.